Evidence map›Paper›PMID 37615179›Full record

ArticleClinical trials (London, England)2024

Controls, comparator arms, and designs for critical care comparative effectiveness research: It's complicated.

Verity J Ford, Harvey G Klein, Robert L Danner, Willard N Applefeld, Jeffrey Wang, Irene Cortes-Puch, Peter Q Eichacker, Charles Natanson

Open access · greenAbstract read
In one paragraph

Article in Clinical trials (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Verity J FordCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Harvey G KleinDepartment of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Robert L DannerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Willard N ApplefeldCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Jeffrey WangCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Irene Cortes-PuchDivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis Medical Center, Sacramento, CA, USA.
Peter Q EichackerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Charles NatansonCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9712-2538
National Institutes of Health Clinical Center · USDuke Medical Center · USUniversity of California Davis Medical Center · US

Funding

Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

backgroundComparative effectiveness research is meant to determine which commonly employed medical interventions are most beneficial, least harmful, and/or most costly in a real-world setting. While the objectives for comparative effectiveness research are clear, the field has failed to develop either a uniform definition of comparative effectiveness research or an appropriate set of recommendations to provide standards for the design of critical care comparative effectiveness research trials, spurring controversy in recent years. The insertion of non-representative control and/or comparator arm subjects into critical care comparative effectiveness research trials can threaten trial subjects' safety. Nonetheless, the broader scientific community does not always appreciate the importance of defining and maintaining critical care practices during a trial, especially when vulnerable, critically ill populations are studied. Consequently, critical care comparative effectiveness research trials sometimes lack properly constructed control or active comparator arms altogether and/or suffer from the inclusion of "unusual critical care" that may adversely affect groups enrolled in one or more arms. This oversight has led to critical care comparative effectiveness research trial designs that impair informed consent, confound interpretation of trial results, and increase the risk of harm for trial participants. METHODS/EXAMPLES: We propose a novel approach to performing critical care comparative effectiveness research trials that mandates the documentation of critical care practices prior to trial initiation. We also classify the most common types of critical care comparative effectiveness research trials, as well as the most frequent errors in trial design. We present examples of these design flaws drawn from past and recently published trials as well as examples of trials that avoided those errors. Finally, we summarize strategies employed successfully in well-designed trials, in hopes of suggesting a comprehensive standard for the field.

conclusionFlawed critical care comparative effectiveness research trial designs can lead to unsound trial conclusions, compromise informed consent, and increase risks to research subjects, undermining the major goal of comparative effectiveness research: to inform current practice. Well-constructed control and comparator arms comprise indispensable elements of critical care comparative effectiveness research trials, key to improving the trials' safety and to generating trial results likely to improve patient outcomes in clinical practice.

Indexed as

ArmComparative Effectiveness ResearchCritical CareHumansInformed ConsentResearch SubjectsComparative effectiveness researchcomparator groupcontrolcritical care clinical trialsmisalignmenttrial designsunusual critical careusual critical care

Identifiers

PMID37615179
PMCPMC10891304
OpenAlexW4386116513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.